| This week's sponsor is Shire. | | Shire Maintains Commitment to ADHD with New Research
Shire will present new research at the American Psychiatric Association (APA) 170th Annual Meeting this week in San Diego, CA. These presentations underscore Shire's long-standing heritage and dedication to advancing research on the unmet medical needs of patients with ADHD.
|
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. |
Featured Story | | | Friday, May 12, 2017 Branded drugmakers weren't the only ones working through a tumultuous 2016. Generics companies faced pricing pressure, too. And while branded companies suffer pricing pain on costly cutting-edge therapies, generics outfits feel the pinch with already-thin margins, making pressure all the more agonizing. |
|
|
Top Stories Of The Week Monday, May 15, 2017 The biotech industry is mourning the loss of one of the sector's founding fathers, Genzyme founder Henri Termeer, who died last week at the age of 71. Monday, May 15, 2017 Next March, GlaxoSmithKline will have the option to buy out Novartis’ stake in the pair’s industry-leading consumer health venture. And it's said to be preparing an offer already. Wednesday, May 17, 2017 The FDA has granted priority review status to Bayer’s copanlisib, setting the PI3K inhibitor up to speed through the regulatory process in six months or less. Bayer secured the privileged position on the strength of data from a midphase trial in patients with non-Hodgkin lymphoma. Tuesday, May 16, 2017 With complex biologics making up a growing part of pipelines, drugmakers have been selling or closing small-molecule plants left and right. Sanofi is taking that process a couple of steps further. It will demolish a plant it spent about $118 million to build and never used. Wednesday, May 17, 2017 No company playing from behind in a competitive market wants to land a serious new safety warning. But that’s exactly the position Johnson & Johnson is in with Type 2 diabetes med Invokana. Monday, May 15, 2017 Metformin has been helping patients with Type 2 diabetes control their blood sugar for more than two decades, but now researchers led by McGill University are investigating a new use for the drug: to treat fragile X syndrome, which causes some forms of autism. Friday, May 12, 2017 Years after winning a hotly anticipated FDA approval for its cancer immunotherapy Provenge—and struggling to build sales of the prostate cancer med—Dendreon has racked up some real-world survival data it hopes can help. Wednesday, May 17, 2017 Robert Califf, the FDA commissioner under President Barack Obama, is in talks with Verily for a leadership position, CNBC reported Tuesday. Monday, May 15, 2017 China's FDA is proposing another round of policy changes designed to hasten clinical trial approval and lift restrictions placed on trial sites, with the ultimate goal of allowing drugs to get into the clinic faster. Resources Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Sponsored By: Veeva To thrive in a fiercely competitive market, life sciences companies need to set themselves apart by designing and executing the best trial and successfully deliver drugs to market first. Learn how a modern EDC can help. Sponsored By Reprints Desk Puzzled by Scientific Literature Access? Here is your guide for navigating knowledge management’s twists and turns! If yours is a small- or medium-sized biopharma business, we can help you putting the pieces together. Learn the secrets of top knowledge management experts who will show you how to search, discover, acquire and manage knowledge in new ways. |
